Introduction to Lung Cancer Animal Models

Lung cancer is one of the malignancies with the highest incidence and mortality worldwide, characterized by strong heterogeneity, a propensity for invasive metastasis, and a poor prognosis, thereby posing a serious threat to human health. Lung cancer animal models—generated through chemical induction, cell‑based xenografts (CDX), patient‑derived xenografts (PDX), orthotopic transplantation, and genetic engineering—can effectively recapitulate the processes of tumorigenesis, progression, and metastasis.

Service Advantages of the Aniphe BioLab Lung Cancer Animal Model Platform

Aniphe BioLab’s lung cancer model platform boasts diversified modeling technologies and a comprehensive assay system, offering end-to-end services to meet the diverse needs of anti‑tumor drug development.

	A wide variety of model types It is capable of generating a variety of lung cancer models, including subcutaneous, orthotopic, metastatic, and carcinogen‑induced models, thereby accommodating diverse research objectives.
	Modeling is stable and efficient. The modeling technique is well-established, with a high tumor‑formation rate, minimal inter‑individual variability, and excellent experimental reproducibility.
	Comprehensive testing system Supports multi-dimensional evaluation, including tumor volume monitoring, pathological analysis, immunohistochemistry, and molecular biomarker testing.
	One-stop customized service We provide end-to-end services, including model establishment, drug administration, sample collection, and assay, with the flexibility to tailor protocols to meet experimental requirements.

Modeling cycle	10–16 weeks
Laboratory animals	Mice and rats, Kras mice
Positive drug	Cisplatin, paclitaxel, gefitinib, and osimertinib are commonly used as positive controls for evaluating the efficacy of chemotherapeutic and targeted agents.
Application areas	It is primarily used for research on the pathogenesis of lung cancer, screening of anti-tumor drugs, evaluation of targeted and immunotherapies, studies of tumor metastasis, validation of therapeutic targets, and preclinical efficacy studies of innovative therapies.

Construction of a Lung Cancer Animal Model

Lung cancer models are established using a variety of well‑validated approaches: primary pulmonary tumors are induced via chemical carcinogens; tumor growth and clinical features are recapitulated in cell‑line–derived xenograft (CDX) and patient‑derived xenograft (PDX) models; and a genetically engineered spontaneous lung cancer model is generated by combining Kras‑mutant mice with Cre‑expressing adenovirus delivered intranasally. These diverse modeling strategies can accommodate a wide range of experimental requirements.